COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,884 Articles (22,568 medRxiv, 8,316 bioRxiv)

Most recent first Previous |  Page 1001: Articles 10001-10010  | Next

The omicron (B.1.1.529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters
Abdelnabi, R., Foo, C. S.-Y., Zhang, X., Lemmens, V., Maes, P., Slechten, B., Raymenants, J., Andre, E., Weynand, B., Dallmeier, K., Neyts, J.
10.1101/2021.12.24.474086 — Posted: 2021-12-26
A subset of Memory B-derived antibody repertoire from 3-dose vaccinees is ultrapotent against diverse and highly transmissible SARS-CoV-2 variants, including Omicron
Wang, K., Jia, Z., Bao, L., Wang, L., Cao, L., Chi, H., Hu, Y., Li, Q., Jiang, Y., Zhu, Q., Deng, Y., Liu, P., Wang, N., Wang, L., Liu, M., Li, Y., Zhu, B., Fan, K., Fu, W., Yang, P., Pei, X., Cui, Z., Qin, L., Ge, P., Wu, J., Liu, S., Chen, Y., Huang, W., Qin, C., Wang, Y., Qin, C., Wang, X.
10.1101/2021.12.24.474084 — Posted: 2021-12-26
Convalescence from prototype SARS-CoV-2 protects Syrian hamsters from disease caused by the Omicron variant
Ryan, K. A., Watson, R. J., Bewley, K. R., Burton, C. A., Carnell, O., Cavell, B. E., Challis, A. R., Coombes, N. S., Emery, K., Fell, R., Fotheringham, S. A., Gooch, K. E., Gowan, K., Handley, A., Harris, D. J., Humphreys, R., Johnson, R., Knott, D., Lister, S., Morley, D., Ngabo, D., Osman, K. L., Paterson, J., Penn, E. J., Pullen, S. T., Richards, K. S., Shaik, I., Summers, S., Thomas, S. R., Weldon, T., Wiblin, N. R., Vipond, R., Hallis, B., Funnell, S. G. P., Hall, Y.
10.1101/2021.12.24.474081 — Posted: 2021-12-26
Two doses of mRNA vaccine elicit cross-neutralizing memory B-cells against SARS-CoV-2 Omicron variant
Kotaki, R., Adachi, Y., Moriyama, S., Onodera, T., Fukushi, S., Nagakura, T., Tonouchi, K., Terahara, K., Sun, L., Takano, T., Nishiyama, A., Shinkai, M., Oba, K., Nakamura-Uchiyama, F., Shimizu, H., Suzuki, T., Matsumura, T., Isogawa, M., Takahashi, Y.
10.1101/2021.12.24.474091 — Posted: 2021-12-26
Remote Covid Assessment in Primary Care (RECAP) risk prediction tool: derivation and real-world validation studies.
Espinosa-Gonzalez, A. B., Prociuk, D., Fiorentino, F., Ramtale, C., Mi, E., Mi, E., Glampson, B., Okusi, C., Macartney, J., Husain, L., Brown, M., Browne, B., Warren, C., Chowla, R., Heaversedge, J., Greenhalgh, T., de Lusignan, S., Delaney, B. C.
10.1101/2021.12.23.21268279 — Posted: 2021-12-25
Ex-vivo mucolytic and anti-inflammatory activity of BromAc in tracheal aspirates from COVID-19
Coelho dos Reis, J. G. A., Marques Ferreira, G., Aparecida Lourenco, A., Lopes Ribeiro, A., Pacheco da Silveira Martins da Mata, C., de Melo Oliveira, P., de Almeida Marques, D. P., Lopes Ferreira, L., Alves Clarindo, F., Ferreira da Silva, M., Portella Povoas Filho, H., Ribeiro Oliveira, N. R., Meyhr D Carmo Sodre, M., Rocha Gadelha, S., Albuquerque, G. R., Mendes Maciel, B., Melo Mariano, A. P., de Melo Silva, M., Fontana, R., Marin, L. J., Santiago Alberto Carlos, R., Teixeira Sampaio Lopes, A., Barbosa Ferreira, F., Ribeiro dos Santos, U., Santos de Santana, I. T., Ferraz Fehlberg, H., Pas
10.1101/2021.12.23.21268347 — Posted: 2021-12-25
Analyzing the interaction of human ACE2 and RBD of spike protein of SARS-CoV-2 in perspective of Omicron variant
Samanta, A., Alam, S. S. M., Ali, S., Hoque, M.
10.1101/2021.12.23.473991 — Posted: 2021-12-25
In vitro evolution predicts emerging CoV-2 mutations with high affinity for ACE2 and cross-species binding
Bate, N., Savva, C. G., Moody, P. C., Brown, E. A., Ball, J. K., Schwabe, J. W., Sale, J., Brindle, N.
10.1101/2021.12.23.473975 — Posted: 2021-12-25
Potential coupling between SARS-CoV-2 replicative fitness and interactions of its nucleoprotein with human 14-3-3 proteins
Tugaeva, K. V., Sysoev, A. A., Smith, J. L. R., Cooley, R. B., Antson, A. A., Sluchanko, N. N.
10.1101/2021.12.23.474009 — Posted: 2021-12-25
An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants
Chi, X., Zhang, X., Pan, S., Yu, Y., Lin, T., Duan, H., Liu, X., Chen, W., Yang, X., Ding, Q., Wang, J., Yang, W.
10.1101/2021.12.25.474052 — Posted: 2021-12-25

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).